Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14847583 | 0.92 | PGR (0.48) | PGRNR3C1ARNR3C2MAPT | |
| SCHEMBL1316094 | 0.91 | PGR (0.42) | PGRNR3C1ARNR3C2MAPT | |
| SCHEMBL1315283 | 0.91 | PGR (0.42) | PGRNR3C1ARNR3C2MAPT | |
| SCHEMBL4417572 | 0.91 | PGR (0.42) | PGRNR3C1ARNR3C2MAPT | |
| SCHEMBL1314463 | 0.90 | PGR (0.45) | PGRNR3C1ARNR3C2MAPT | |
| SCHEMBL1315958 | 0.90 | PGR (0.43) | PGRNR3C1ARNR3C2MAPT | |
| SCHEMBL1780838 | 0.89 | PGR (0.40) | PGRNR3C1ARNR3C2MAPT | |
| SCHEMBL1314939 | 0.88 | PGR (0.43) | PGRNR3C1ARNR3C2MAPT | |
| SCHEMBL1315881 | 0.88 | PGR (0.47) | PGRNR3C1ARNR3C2MAPT | |
| SCHEMBL13618797 | 0.87 | PGR (0.39) | PGRNR3C1ARNR3C2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440660-B2 | Method for treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8440660-B2 | Method for treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| EP-2085387-B1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-04-10 | — | — | EP | disclosed |
| EP-2085387-B1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20110275620-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275620-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-8008496-B2 | 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008496-B2 | 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20100056504-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER- INTRODUCED PHENYL GROUP AS SUBSTITUENTS | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056504-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER- INTRODUCED PHENYL GROUP AS SUBSTITUENTS | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2085387-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-08-05 | — | — | EP | disclosed |
| EP-2085387-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056504-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER- INTRODUCED PHENYL GROUP AS SUBSTITUENTS | NR3C1, NR3C2, NR5A1 | PGR 54/4885NR3C1 1/4885AR 94/4885 |
| US-20110275620-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | NR3C1, NR3C2, NR5A1 | PGR 183/4885NR3C1 1/4885AR 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.